ELAN
Price
$22.60
Change
+$0.22 (+0.98%)
Updated
Dec 26 closing price
Capitalization
11.23B
59 days until earnings call
Intraday BUY SELL Signals
NBIX
Price
$145.26
Change
-$1.67 (-1.14%)
Updated
Dec 26 closing price
Capitalization
14.48B
45 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs NBIX

Header iconELAN vs NBIX Comparison
Open Charts ELAN vs NBIXBanner chart's image
Elanco Animal Health
Price$22.60
Change+$0.22 (+0.98%)
Volume$2.55M
Capitalization11.23B
Neurocrine Biosciences
Price$145.26
Change-$1.67 (-1.14%)
Volume$693.79K
Capitalization14.48B
ELAN vs NBIX Comparison Chart in %
ELAN
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ELAN vs. NBIX commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Buy and NBIX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (ELAN: $22.60 vs. NBIX: $145.26)
Brand notoriety: ELAN: Notable vs. NBIX: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 44% vs. NBIX: 65%
Market capitalization -- ELAN: $11.23B vs. NBIX: $14.48B
ELAN [@Pharmaceuticals: Generic] is valued at $11.23B. NBIX’s [@Pharmaceuticals: Generic] market capitalization is $14.48B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 1 FA rating(s) are green whileNBIX’s FA Score has 0 green FA rating(s).

  • ELAN’s FA Score: 1 green, 4 red.
  • NBIX’s FA Score: 0 green, 5 red.
According to our system of comparison, ELAN is a better buy in the long-term than NBIX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 8 TA indicator(s) are bullish while NBIX’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 8 bullish, 2 bearish.
  • NBIX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than NBIX.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +1.35% price change this week, while NBIX (@Pharmaceuticals: Generic) price change was +0.18% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.01%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +23.01%.

Reported Earning Dates

ELAN is expected to report earnings on Feb 25, 2026.

NBIX is expected to report earnings on Feb 11, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.01% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($14.5B) has a higher market cap than ELAN($11.2B). ELAN has higher P/E ratio than NBIX: ELAN (322.86) vs NBIX (34.67). ELAN YTD gains are higher at: 86.623 vs. NBIX (6.418). ELAN has higher annual earnings (EBITDA): 840M vs. NBIX (613M). NBIX has more cash in the bank: 1.12B vs. ELAN (505M). NBIX has less debt than ELAN: NBIX (428M) vs ELAN (4.02B). ELAN has higher revenues than NBIX: ELAN (4.59B) vs NBIX (2.68B).
ELANNBIXELAN / NBIX
Capitalization11.2B14.5B77%
EBITDA840M613M137%
Gain YTD86.6236.4181,350%
P/E Ratio322.8634.67931%
Revenue4.59B2.68B171%
Total Cash505M1.12B45%
Total Debt4.02B428M940%
FUNDAMENTALS RATINGS
ELAN vs NBIX: Fundamental Ratings
ELAN
NBIX
OUTLOOK RATING
1..100
1676
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
10054
SMR RATING
1..100
9054
PRICE GROWTH RATING
1..100
4050
P/E GROWTH RATING
1..100
257
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NBIX's Valuation (74) in the Biotechnology industry is in the same range as ELAN (94) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew similarly to ELAN’s over the last 12 months.

NBIX's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than ELAN’s over the last 12 months.

NBIX's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for ELAN (90) in the Agricultural Commodities Or Milling industry. This means that NBIX’s stock grew somewhat faster than ELAN’s over the last 12 months.

ELAN's Price Growth Rating (40) in the Agricultural Commodities Or Milling industry is in the same range as NBIX (50) in the Biotechnology industry. This means that ELAN’s stock grew similarly to NBIX’s over the last 12 months.

ELAN's P/E Growth Rating (2) in the Agricultural Commodities Or Milling industry is somewhat better than the same rating for NBIX (57) in the Biotechnology industry. This means that ELAN’s stock grew somewhat faster than NBIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANNBIX
RSI
ODDS (%)
Bullish Trend 3 days ago
74%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
78%
Bullish Trend 3 days ago
67%
Momentum
ODDS (%)
Bullish Trend 3 days ago
56%
Bearish Trend 3 days ago
60%
MACD
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 3 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
70%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 3 days ago
64%
Bullish Trend 7 days ago
71%
Declines
ODDS (%)
Bearish Trend 20 days ago
72%
Bearish Trend 3 days ago
56%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
72%
Aroon
ODDS (%)
Bullish Trend 3 days ago
69%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signal:
Gain/Loss:
NBIX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
FEMS42.390.12
+0.28%
First Trust Emerg Mkts SC AlphaDEX® ETF
FAUG53.240.03
+0.06%
FT Vest US Equity Buffer ETF Aug
CSTK29.21N/A
N/A
Invesco Comstock Contrarian Equity ETF
SPBC45.25-0.01
-0.01%
Simplify US Equity PLUS Bitcoin Stgy ETF
PTIR31.77-1.88
-5.59%
GraniteShares 2x Long PLTR Daily ETF

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+0.98%
VTRS - ELAN
48%
Loosely correlated
+0.65%
ZTS - ELAN
47%
Loosely correlated
+0.59%
PAHC - ELAN
40%
Loosely correlated
+1.14%
SNDL - ELAN
39%
Loosely correlated
-2.26%
AMRX - ELAN
37%
Loosely correlated
+0.62%
More

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with TEVA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then TEVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-1.14%
TEVA - NBIX
35%
Loosely correlated
+0.47%
EOLS - NBIX
31%
Poorly correlated
+0.73%
AQST - NBIX
30%
Poorly correlated
+0.34%
ELAN - NBIX
30%
Poorly correlated
+0.98%
AMRX - NBIX
28%
Poorly correlated
+0.62%
More